COVID-19 Made Its Mark On the R&D Pipeline And Novel Drug Launches In 2020
A new analysis reveals the impact of the coronavirus pandemic on pharma R&D in 2020 in two quarters: the total size of the pipeline and in the number of novel products launched in their first markets.
You may also be interested in...
In this one-off podcast, hear in the inside story of how the Pharmaprojects’ Pharma R&D Annual Review 2021 is put together, its history and the trends it has revealed in R&D over the years.
INFOGRAPHIC: A snapshot of the industry in key performance indicators surrounding R&D taken in early 2021.
AstraZeneca and Sanofi have leapt forward in their plans to shake up the RSV market with earlier than expected positive data for their passive immunization product nirsevimab. Rival maternal vaccines in development will cast a shadow, however.